Endoglin (CD 105) as a potential prognostic factor in neuroblastoma
- 12 February 2015
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (5) , 770-775
Abstract
Background: Endoglin (CD105) is a cytokine that modulates angiogenesis by regulating different cellular functions, including endothelial proliferation, differentiation, migration and formation of microvessels. CD105 is expressed strongly in the tumor vasculature, and intratumoral microvessel density (IMVD), as determined by the use of antibodies to CD105, it has been found to be an important prognostic indicator for outcome in various malignances. This study aims to determine if the clinical outcome of children with neuroblastoma is correlated with IMVD, as determined by CD105 staining and other prognostic factors.Procedure: Tumor tissue specimens from 38 patients with peripheral neuroblastic tumors who underwent surgical resection or biopsy of their primary tumor without any preoperative therapy were retrospectively reviewed. IMVD was identified immunohistochemically using monoclonal antibodies against CD105. Prognostic factors, such as the MYCN oncogene, disease stage, histopathology and age, were correlated with outcome.Results: Among 38 examined specimens, the median IMVD value was 23.2 (15.1–28.4). The IMVD identified by CD105 was significantly higher in patients with unfavorable histology, metastatic disease, MYCN amplification and COG high risk group. ROC analysis was used to find significant IMVD level regarding EFS. The cut‐off >18 was selected according to the greatest sensitivity (100%) and specificity (68.42%). The multivariate Cox proportional hazards analysis demonstrated that MYCN amplification and IMVD were significant prognostic factors in predicting EFS (hazard ratio for MYCN amplification: 3.61; 95% CI: 1.20–10.90; P = 0.023 and for IMVD: 1.05; 95% CI: 1.00–1.09; P = 0.037).Conclusion: IMVD determined by CD105 appeared to be an independent prognostic factor for neuroblastoma. Pediatr Blood Cancer 2015;62:770–775.Keywords
This publication has 42 references indexed in Scilit:
- CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34Virchows Archiv, 2013
- Nanocarrier-Mediated Targeting of Tumor and Tumor Vascular Cells Improves Uptake and Penetration of Drugs into NeuroblastomaFrontiers in Oncology, 2013
- Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancersExperimental and Therapeutic Medicine, 2012
- NeuroblastomaSeminars in Pediatric Surgery, 2012
- International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteeBritish Journal of Cancer, 2009
- Angiogenesis as a target in neuroblastomaEuropean Journal of Cancer, 2008
- Prominent Microvascular Proliferation in Clinically Aggressive NeuroblastomaClinical Cancer Research, 2007
- Mechanisms of invasion and metastasis in human neuroblastomaCancer and Metastasis Reviews, 2006
- Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluationEuropean Journal of Cancer, 1996
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990